Table 1.

SGLT2i and atrasentan current (15 April 2019) indications and use in renal disease by the EMA [42–44]

Indications

Canagliflozin, dapagliflozin and empagliflozin: adults with insufficiently controlled T2DM as an adjunct to diet and exercise, either as monotherapy when metformin is considered inappropriate due to intolerance or in addition to other medicinal products for the treatment of diabetes.

Dapagliflozin: adults with insufficiently controlled T1DM as an adjunct to insulin in patients with BMI ≥27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

Atrasentan: no indication, experimental drug.

Use in renal disease patients

Canagliflozin, dapagliflozin or empagliflozin should not be initiated in patients with an eGFR <60 mL/min/1.73 m2 and should be discontinued at a GFR persistently <45 mL/min/1.73 m2.